Defining the role of abciximab for acute coronary syndromes: lessons from CADILLAC, ADMIRAL, GUSTO IV, GUSTO v, and TARGET

Citation
Aw. Chan et Dj. Moliterno, Defining the role of abciximab for acute coronary syndromes: lessons from CADILLAC, ADMIRAL, GUSTO IV, GUSTO v, and TARGET, CURR OPIN C, 16(6), 2001, pp. 375-383
Citations number
59
Language
INGLESE
art.tipo
Review
Categorie Soggetti
Cardiovascular & Respiratory Systems
Journal title
CURRENT OPINION IN CARDIOLOGY
ISSN journal
0268-4705 → ACNP
Volume
16
Issue
6
Year of publication
2001
Pages
375 - 383
Database
ISI
SICI code
0268-4705(200111)16:6<375:DTROAF>2.0.ZU;2-V
Abstract
Acute coronary syndromes (ACS), including those associated with or without ST-segment elevation, share a common pathophysiology mediated by activated platelets and thrombin. It is becoming increasingly appreciated that reperf usion therapies using primary mechanical or pharmacologic strategies result in suboptimal reperfusion at the myocardial tissue level. Complete reperfu sion of the coronary microvasculature has recently been shown to be an impo rtant predictor for survival following myocardial infarction. Abciximab has well-established clinical benefits in numerous interventional trials. Thro ugh its anti-platelet and anti-thrombotic activities, abciximab reduces thr ombus formation and hence minimizes risk of thrombotic microvascular emboli zation and improves tissue-level reperfusion. Several recent landmark trial s have evaluated the clinical efficacy of adjunctive abciximab during mecha nical or pharmacologic reperfusion therapy in the setting of ACS. This arti cle provides an update of the role of abciximab in the treatment for ACS ba sed on the results of these clinical trials. (C) 2001 Lippincott Williams & Wilkins, Inc.